Objective: It is generally recognized that obesity and cardiometabolic risk are more prevalent in African Americans. Kallistatin, a novel tissue kallikrein inhibitor, has anti-inflammatory and anti-oxidant properties. Thus, the goal of this study was to examine the relationships among plasma kallistatin levels, adiposity and cardiometabolic risk factors in African American adolescents. Materials/Methods: Plasma kallistatin levels were determined in 318 apparently healthy African American adolescents (aged 14-19 years, 48.1% females) by enzyme-linked immunosorbent assay. Results: Plasma kallistatin levels did not differ between males (27.9 ± 11.2 μg/mL) and females (26.8 ± 11.0 μg/mL) (p = 0.47). Plasma kallistatin levels were inversely correlated with percent body fat (% BF, r = - 0.13, p = 0.04), total cholesterol (r = - 0.28, p < 0.01), low density lipoprotein cholesterol (LDL, r = - 0.30, p < 0.01) and interleukin-6 (r = - 0.14, p = 0.05), but positively correlated with adiponectin (r = 0.16, p = 0.03) and high density lipoprotein (HDL, r = 0.17, p = 0.02). These correlations remained significant after adjustment for age, sex and body mass index percentiles. Stepwise multiple linear regression analysis showed that LDL cholesterol alone explained 14.2% of the variance in kallistatin, while % BF and adiponectin explained an additional 3.6% and 2.8% of the variance, respectively. Conclusions: The present study demonstrates that plasma kallistatin levels are inversely associated with adiposity, adverse lipid profiles and inflammation in apparently healthy African American adolescents. As a potent antioxidant and anti-inflammation agent, kallistatin may also hold therapeutic promise in cardiometabolic disorders.
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism